Cargando…

Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide

OBJECTIVE: Isocitrate dehydrogenase (IDH)-wildtype glioblastomas are the most malignant glial tumours. Median survival is only 14–16 months after diagnosis, with patients aged ≥ 65 years reportedly showing worse outcome. This study aimed to further evaluate the prognostic role of age in a homogenous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berger, Kerstin, Turowski, Bernd, Felsberg, Jörg, Malzkorn, Bastian, Reifenberger, Guido, Steiger, Hans-Jakob, Budach, Wilfried, Haussmann, Jan, Knipps, Johannes, Rapp, Marion, Hänggi, Daniel, Sabel, Michael, Mijderwijk, Hendrik-Jan, Kamp, Marcel A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article – Clinical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810639/ https://www.ncbi.nlm.nih.gov/pubmed/32748120 http://dx.doi.org/10.1007/s00432-020-03334-3

Ejemplares similares

Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
por: Mareike, Müller, et al.
Publicado: (2021)

Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[(18)F]-fluoroethyl)-l-tyrosine PET
por: Bauer, Elena K., et al.
Publicado: (2020)

Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses
por: Liu, Yu-Qing, et al.
Publicado: (2019)

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
por: Radke, Josefine, et al.
Publicado: (2019)

Risk factors for in-brain local progression in elderly patients after resection of cerebral metastases
por: Munoz-Bendix, Christopher, et al.
Publicado: (2019)

Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement
por: Rosen, Jurij, et al.
Publicado: (2021)

Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022)

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
por: Diplas, Bill H., et al.
Publicado: (2018)

Droplet digital PCR-based analyses for robust, rapid, and sensitive molecular diagnostics of gliomas
por: Wolter, Marietta, et al.
Publicado: (2022)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status
por: Unger, Kristian, et al.
Publicado: (2020)

Methylation class oligosarcoma may encompass IDH-wildtype gliomas
por: Ebrahimi, Azadeh, et al.
Publicado: (2022)

PDPN contributes to constructing immunosuppressive microenvironment in IDH wildtype glioma
por: Wang, Xuya, et al.
Publicado: (2022)

Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
por: Liu, Elisa K, et al.
Publicado: (2022)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

5-ALA fluorescence of cerebral metastases and its impact for the local-in-brain progression
por: Kamp, Marcel A., et al.
Publicado: (2016)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma
por: Saaid, Ayoub, et al.
Publicado: (2022)

Radiobiology of Radiosurgery for the Central Nervous System
por: Santacroce, Antonio, et al.
Publicado: (2013)

GEN-13 FIREWORK PATTERN OF CANCER GENESIS FOR GLIOBLASTOMA, IDH-WILDTYPE
por: Yoon, Seon-Jin, et al.
Publicado: (2019)

A Simple Preoperative Blood Count to Stratify Prognosis in Isocitrate Dehydrogenase-Wildtype Glioblastoma Patients Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide
por: Clavreul, Anne, et al.
Publicado: (2021)

Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities
por: Garrett, Matthew, et al.
Publicado: (2018)

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022)

Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype: case series of a new entity
por: Bender, Katja, et al.
Publicado: (2023)

Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma
por: Jungk, Christine, et al.
Publicado: (2019)

Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres
por: Yoon, Seon-Jin, et al.
Publicado: (2020)

Glioblastoma, IDH-wildtype: A New Association with IgM Paraproteinaemic Neuropathy?
por: Lewis, Dana M., et al.
Publicado: (2022)

Glioblastoma, IDH-wildtype with leptomeningeal metastasis to Meckel’s cave: A case report
por: Murata, Toshiki, et al.
Publicado: (2022)

Initial Treatment of IDH-Wildtype Glioblastoma in Adults Older Than 70 Years
por: Bao, Jing, et al.
Publicado: (2023)

Distribution and favorable prognostic implication of genomic EGFR alterations in IDH ‐wildtype glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide
por: Vargas-Toscano, Andres, et al.
Publicado: (2020)

Synthetic vascular grafts as a new treatment option for space-occupying tumor bed cysts
por: Schieferdecker, Simon, et al.
Publicado: (2022)

Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery
por: Stummer, Walter, et al.
Publicado: (2012)

Psychooncological distress in low-grade glioma patients—a monocentric study
por: Ley, Alessandra, et al.
Publicado: (2021)

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021)

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2020)

Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions
por: Mata, Douglas A., et al.
Publicado: (2020)

MPC-02 Prognostic effects of molecular factors in elderly patients with IDH-wildtype Glioblastomas
por: Fukai, Junya, et al.
Publicado: (2020)

High-dose radiation associated with improved survival in IDH-wildtype low-grade glioma
por: Liu, Shuai, et al.
Publicado: (2021)

Newly Diagnosed IDH-Wildtype Glioblastoma and Temporal Muscle Thickness: A Multicenter Analysis
por: Wende, Tim, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_icedrdk3d352kkt0frbkhoci2v